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Abstract: 
Background: Central nervous system (CNS) relapse of diffuse large B-cell lymphoma 
(DLBCL) is associated with a dismal prognosis. Here we report an analysis of CNS 
relapse for patients treated within the UK NCRI phase III R-CHOP 14 versus 21 
randomised trial.  
Patients and Methods: The R-CHOP 14 versus 21 trial compared rituximab, 
cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) 
administered 2- versus 3-weekly in previously untreated patients aged ≥18 years with 
bulky stage I-IV DLBCL (n=1,080). Details of CNS prophylaxis were retrospectively 
collected from participating sites. The incidence of and risk factors for CNS relapse 
including application of the CNS-IPI were evaluated. 
Results: 177/984 patients (18.0%) received prophylaxis (intrathecal (IT) methotrexate 
(MTX) n=163, intravenous (IV) MTX n=2, prophylaxis type unknown n=11 and IT 
MTX and cytarabine n=1). At a median follow-up of 6.5 years, 21 cases of CNS 
relapse (isolated n=11, with systemic relapse n=10) were observed, with a 
cumulative incidence of 1.9%. For patients selected to receive prophylaxis the 
incidence was 2.8%. Relapses predominantly involved the brain parenchyma 
(81.0%) and isolated leptomeningeal involvement was rare (14.3%). Univariable 
analysis (UVA) demonstrated the following risk factors for CNS relapse: PS 2, 
elevated LDH, IPI, >1 extranodal site of disease and presence of a ‘high-risk’ 
extranodal site. Due to the low number of events no factor remained significant in 
multivariate analysis (MVA). Application of the CNS-IPI revealed a high-risk group (4-
6 risk factors) with a 2 and 5-year incidence of CNS relapse of 5.2% and 6.8% 
respectively. 
Conclusion: Despite very limited use of IV MTX as prophylaxis, the incidence of CNS 
relapse following R-CHOP was very low (1.9%) confirming the reduced incidence in 
the rituximab era. The CNS-IPI identified patients at highest risk for CNS recurrence.  
 
Trial number: ISCRTN 16017947 (R-CHOP14v21) 
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Key message 
We provide a detailed analysis of CNS relapse for patients with diffuse large B-cell 
lymphoma treated within the phase 3 UK NCRI R-CHOP14 v21 trial. Our data 
demonstrate a very low incidence of CNS relapse in a uniformly R-CHOP-treated trial 
population despite limited use of intravenous methotrexate as prophylaxis. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Introduction: 
CNS relapse is a devastating complication of diffuse large B-cell lymphoma (DLBCL) 
associated with a median survival of 2-5 months.[1] The risk appears to be less in the 
rituximab era[2, 3] however the data is conflicting, with a decreased incidence in 
some [4–9] but not all reported series.[10–13]  
Chemoprophylaxis frequently with IT or IV MTX, is a longstanding strategy aiming to 
reduce the risk of CNS recurrence in DLBCL; however there is a risk of associated 
toxicity and limited evidence of efficacy. As the reported incidence of CNS relapse in 
the rituximab era in the absence of prophylaxis is 5.4%[10] administration is currently 
limited to high-risk patients.  
Several risk factors for CNS recurrence have been reported including involvement of 
various extranodal (EN) sites by lymphoma at baseline, involvement of >1 EN site of 
disease (alone or in combination raised lactate dehydrogenase (LDH) level), as well 
as a high-intermediate/high-risk International Prognostic Index (IPI) score, which are 
well-summarised by McMillan et al[2]. In addition several biomarkers including 
activated B-cell (ABC) subtype [14], dual expression of MYC and BCL-2 by 
immunohistochemistry (IHC) [14] or MYC or double-hit rearrangement [15] are 
associated with increased risk. 
Recently the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) 
reported a 6-factor prognostic model, the CNS-IPI, incorporating the 5 IPI factors and 
presence or absence of kidney and/or adrenal gland involvement to determine the 
risk of CNS relapse for patients with aggressive B-cell lymphoma. This model 
stratified patients into 3 risk groups for CNS relapse at 2 years: low [0-1 factors, 0.6% 
(95% CI 0-1.2) ]; intermediate [2-3 factors, 3.4 % (95% CI 2.2-4.4)] and high risk [4-6 
factors,10.2% (95% CI 6.3-14.1)]; and was subsequently validated in an independent 
population-based cohort of R-CHOP-treated patients with DLBCL from the British 
Columbia Cancer Agency (BCCA). [16] 
Here we report an analysis evaluating CNS relapse for patients enrolled within the 
prospective randomised UK NCRI R-CHOP-14 versus 21 trial, including an 
evaluation of the CNS-IPI within this cohort and data regarding delivery of 
prophylaxis. 
 
 
Patients and Methods: 
The phase III randomised R-CHOP 14 versus 21 trial compared R-CHOP 
administered 2-weekly versus 3-weekly in the first-line treatment of DLBCL. A total of 
1,080 patients aged ≥18 years with previously untreated bulky stage I-IV DLBCL 
were enrolled at 119 centres across the UK between March 2005 and November 
2008. We previously reported that the primary endpoint of superior overall survival 
(OS) with R-CHOP-14 compared to R-CHOP-21 was not met, and that R-CHOP-14 
was not superior to R-CHOP-21 for progression-free survival (PFS), response rate or 
safety.[17] Patients with primary mediastinal B-cell lymphoma (PMBL) were not 
excluded from trial participation and we recently reported our outcomes for this 
subgroup of patients. [18] 
In accordance with the study protocol administration of CNS prophylaxis (12.5mg IT 
MTX) with the first 3 cycles of treatment or according to local guidelines) was at the 
discretion of the local investigator, but recommended for patients with involvement of 
bone marrow, peripheral blood, nasal/paranasal sinuses, orbit and testis. Details of 
CNS prophylaxis were retrospectively collected from participating sites using case 
report forms (CRFs).  
The study database was interrogated to identify all cases where the CNS was 
documented as a site of relapse at initial disease progression. To ensure that all 
cases were captured local investigators reporting progressive disease (PD) were 
also contacted to confirm if the CNS was a site of involvement. Where a case of CNS 
relapse was identified investigators were asked to confirm the site(s) involved.  
The primary endpoint of this analysis was to determine the incidence of CNS relapse. 
PFS and OS were calculated from the date of registration, censored at the date last 
seen, and analysed using Kaplan-Meier (KM) method.  
Univariable and multivariable Cox regression analyses were performed to investigate 
the risk factors for CNS relapse. The Chi-Squared Test or Fisher’s exact test were 
used to compare the demographics between the following groups: group 1 (disease-
free, n=795), group 2 (systemic relapse, n=264) versus group 3 + 4 (CNS relapse 
(n=21: non-isolated n=10, isolated n=11). 
The following parameters were assessed: sex, age (≤60 versus >60 years), WHO 
performance status (PS) (<2 versus 2), stage (I/II versus III/IV), bulky disease >10cm 
(present versus absent), B symptoms (present versus absent), elevated LDH 
(present versus absent), IPI (0,1,2,3,4,5), >1 extranodal site (present versus absent),  
presence of a ‘high-risk’ extranodal site (bone, bone marrow, breast, kidney, orbit, 
nasal/paranasal sinuses, epidural space, peripheral blood and testis)  (present 
versus absent), trial arm (R-CHOP-14 versus R-CHOP-21), CNS prophylaxis (yes 
versus no), cell-of-origin (COO) by Hans[19] algorithm (germinal centre B-cell (GCB) 
versus non-GCB subtype), BCL 2 translocation by fluorescence in-situ hybridization 
(FISH) (present versus absent),  BCL 6 rearrangement by FISH (present versus 
absent), MYC rearrangement by FISH (present versus absent), double-hit by FISH 
(present versus absent), MIB1 (<90 versus ≥90), MIB1 (<80 versus ≥80), COO 
determined by gene expression profiling (GEP) (GCB versus ABC versus Type 
III/unclassified). 
The CNS-IPI was then applied to our cohort to investigate the incidence of CNS 
relapse according to CNS-IPI risk group. 
Results: 
Key baseline characteristics for the entire trial cohort are shown in Table 1.   
CRFs outlining CNS prophylaxis details administered on study were returned in 
984/1080 (91.1%) cases, with data missing for 96 cases. A total of 177/984 patients 
(18.0%) received CNS prophylaxis within the trial. The type of prophylaxis 
administered was IT-MTX (163/177), IV-MTX (2/177), IT MTX and IT cytarabine 
(1/177) and prophylaxis type unknown (11/177). Table 2 shows the proportion of 
patients receiving CNS prophylaxis by EN sites of DLBCL involvement at baseline.  
Twenty-three potential cases of CNS relapse were identified. Of these, 2 were 
excluded following discussion with the local investigator due to (1) presence of a 
spinal mass which did not penetrate the dura mater and (2) CNS relapse occurred 
subsequent to initial disease progression. At a median follow-up of 6.5 years, the 
number of confirmed cases of CNS relapse was 21/1080 (1.9%), including one 
patient from the PMBL cohort. Over half the events were isolated (n=11), with the 
remainder occurring in association with recurrence of systemic disease (n=10); and 
the majority (14/21) occurred in the first-year following study registration. The 
incidence of CNS relapse was 2.0% (16/807) if prophylaxis was not administered and 
2.8% (5/177) for those who received prophylaxis, or 2.5% (4/163) for patients who 
received IT-MTX.   
Baseline characteristics for patients with CNS relapse are shown in Tables 1 and 
Supplementary Table 1. Data on molecular subtyping (Illumina DASL® platform) was 
available for 4/21 patients classified as GCB n=2, ABC n=1 and type III/unclassifiable 
n=1 subtypes accordingly. CNS relapse predominantly involved the brain 
parenchyma (17/21, 81.0%), for 14/17 this was the only site of CNS relapse, 2/17 
had concurrent spinal cord involvement and 1/17 had concurrent leptomeningeal 
infiltration. Three patients (3/21, 14.3%) had isolated leptomeningeal involvement 
and for 1 patient (1/21) had a CNS relapse diagnosed on clinical grounds following 
presentation with a facial nerve palsy and arm weakness in association with 
increased protein in the cerebrospinal fluid (CSF).  
The median time to progression for a CNS and systemic relapse was 8.1 months 
(95% CI: 1.0-15.1), and 10.9 months (95% CI: 9.2-12.6) respectively. OS from study 
registration comparing relapse-free versus systemic relapse versus CNS relapse 
patient groups is shown in Figure 1. The median OS following a diagnosis of CNS 
relapse was 3.5 months (95% CI: 0.1–6.9) and 7.7 months (95% CI: 6.0–9.4) 
following a systemic relapse.  
Significant risk factors for CNS relapse by UVA were: WHO PS 2 (p=0.001), elevated 
LDH (p=0.042), IPI (p=0.004), >1 EN site of disease (p<0.001) and presence of a 
‘high-risk’ EN site (p=0.001) (Supplementary Table 2). No factor remained 
independently significant in MVA based on these 21 cases.  
Applying the CNS-IPI patients were categorised as low-risk=313/1080 (29.0%), 
intermediate-risk 563/1080 (52.1%) and high-risk=204/1080 (18.9%) accordingly. 
The proportion receiving CNS prophylaxis was 15.3%, 14.4% and 31.4% in each 
group respectively. The number of CNS relapses by group were: low-risk=2, 
intermediate-risk=8 and high-risk=11; with a 2-year [0%, 1.2% (95% CI 0.2- 2.2%) 
and 5.2% (95% CI 1.9-8.5%)]; and 5-year [0.8% (95% CI 0-2.0%), 1.7% (95% CI 0.5-
2.9%) and 6.8% (95% CI 2.9-10.7%)] incidence of CNS relapse accordingly (Figure 
2). Adjusting for CNS-IPI risk group according to use of CNS prophylaxis did not 
demonstrate a clinical benefit [HR=1.12 (95% CI: 0.40-3.14, p=0.83)] 
(Supplementary Table 3). 
Discussion: 
At a median follow-up of 6.5 years the cumulative incidence of CNS relapse of 1.9% 
following R-CHOP was very low. The majority of relapses involved the brain 
parenchyma and isolated leptomeningeal involvement was rare. Relapses in the 
CNS tended to occur earlier than systemic relapse, and most (14/21) occurred within 
the first year following registration. Consistent with prior studies[1] the prognosis 
following CNS relapse in our cohort was poor, with a median OS of 3.5 months. One 
patient with CNS relapse was from the recently reported PMBL subgroup analysis 
equating to an incidence of CNS relapse for this cohort of 2.0% (1/50), consistent 
with published reports in the rituximab era.[20] Although several risk factors for CNS 
relapse were identified on UVA, none remained independently significant in MVA due 
to the low number of events. None of the biomarkers tested were significant in UVA, 
but this must be interpreted in the context of low numbers tested. Application of the 
CNS-IPI identified a high-risk group with 2 and 5-year incidences of CNS relapse of 
5.2% and 6.8% respectively, providing further validation for this risk model. The 
incidence of CNS relapse for patients selected to receive prophylaxis was 2.8% 
(2.5% for patients who received IT-MTX) which might suggest some efficacy for this 
therapy; however when we evaluated the CNS-IPI adjusting for prophylaxis use, no 
benefit could be demonstrated overall, although small numbers in some individual 
groups limits interpretation. Five patients who developed subsequent CNS 
recurrence (parenchymal n=4, isolated leptomeningeal n=1) received IT MTX 
prophylaxis (Supplementary Table 1), highlighting the potential for treatment-failures 
with this approach. 
The strength of our analysis lies in the evaluation of an unselected cohort of DLBCL 
patients aged ≥18 years who were uniformly R-CHOP-treated within in the setting of 
a large multicentre prospective clinical trial. The long duration of follow-up is an 
additional strength given the propensity for late-onset recurrences. However as a 
retrospective evaluation of a prospective trial, the analysis was not pre-planned and 
the study was not designed or powered at the outset to evaluate this particular 
endpoint. The low number of CNS events also precluded the identification of 
independent risk factors.   
Evaluation of CNS relapse in DLBCL poses several challenges for researchers due 
to its rarity. Comparison between studies is also inherently difficult due to the 
heterogeneity of the populations reported in the literature, some of which are 
selected[4, 6, 10, 12, 13], or include patients with other aggressive B-cell lymphoma 
histologies as well as DLBCL.[4, 16, 21] Variation in prophylaxis use between 
cohorts further complicates data interpretation.  
The addition of rituximab to CHOP has consistently improved outcomes for patients 
with previously untreated DLBCL, but the impact on preventing CNS recurrence is 
more controversial.[4–13, 22] On the whole consensus opinion supports the view that 
there has been a reduction in CNS relapse in the rituximab era consequent to 
improved control of systemic disease.[2, 3] 
The pattern of CNS relapse in DLBCL also appears to have evolved with rituximab, 
with relapses increasingly involving the brain parenchyma rather than the 
leptomeninges[1, 7, 8], the latter being more prevalent previously.[1] A higher 
proportion of CNS recurrences occurring in isolation are also reported for rituximab-
treated patients[4, 6] similarly attributed to improved systemic disease control.  
Although we also identified a high-risk CNS-IPI group, overall we observed a lower 
incidence of CNS relapse across all risk groups than that reported by Schmitz et 
al[16] and the distinction between low and intermediate-risk was less clearly defined 
in our analysis. This may be explained by differences between the cohorts studied, 
for example, patients evaluated by the BCCA were older with a higher proportion of 
patients with increased PS (>2) and IPI, as anticipated with a population-based 
cohort, in contrast to our trial population where patients with PS >2 were excluded 
from participation, which may have led to fewer CNS events. Furthermore the 
indications for CNS prophylaxis differed between studies, in the DSHNHL trials 
prophylaxis was mandated for patients with involvement of bone marrow, testes or 
involvement of lymph nodes of the head and neck in 5/8 of these studies[16], while 
for the BCCA validation cohort prophylaxis was administered to patients with sinus 
involvement only  for the main duration of accrual.   
Controversy surrounds CNS prophylaxis given the limited and conflicting evidence-
base, potential associated toxicity, and consequent demand placed on hospital 
services. In practice IT MTX is the most widely used prophylaxis, and while several 
studies support this approach[23, 24], not all have demonstrated benefit.[4, 11] 
Concerns also exist regarding IT administration in terms of preventing parenchymal 
relapses in particular.[2, 6] As systemic MTX is the mainstay of therapy for primary 
CNS lymphoma (PCNSL) and given the reported efficacy as CNS prophylaxis [25] 
many advocate this mode of administration. In our analysis however only a minority 
of patients (n=2) received IV MTX but despite this, the risk of CNS recurrence was 
extremely low, even in patients deemed to be high-risk at the outset. 
In conclusion, our findings demonstrate a reduction in CNS relapse rates in the 
rituximab era. For patients selected to receive prophylaxis, the incidence of CNS 
relapse was 2.8%, which might suggest some benefit, possibly reflected by a low 
incidence of leptomeningeal relapse (where the IT route of administration is most 
likely to exert effect); although an exploratory analysis of CNS-IPI group adjusted for 
prophylaxis use did not show an overall risk reduction. The low number of CNS 
events we observed overall also calls into question the additional benefit of using IV 
MTX in this setting, given the potential for increased toxicity. Ultimately randomised 
clinical trials are required to determine the optimal approach in high-risk patients. In 
the future incorporation of novel agents such as lenalidomide, ibrutinib, and 
nivolumab, which are currently being evaluated in combination with R-CHOP, may 
conceivably reduce CNS relapse rates even further in DLBCL given the emerging 
data on their efficacy in relapsed or refractory PCNSL in the recently reported clinical 
studies NCT01956695, NCT02542514 and NCT02857426 respectively. 
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Table 1: Key baseline characteristics for the R-CHOP 14 versus 21 trial cohort  (n=1080) 
and for patients with CNS relapse (n=21) 
 R-CHOP 14 versus 21 
cohort 
Patients with CNS 
relapse 
 N=1080  N=21 
Median age (range), years 61 (19-88) 59 (38-78) 
Age ≤60 years 
Age >60 years 
476 (44.1%) 
604 (55.9%) 
11 (52.4%) 
10 (47.6%) 
Gender 
             Male 
             Female 
 
582 (53.9%) 
498 (46.1%) 
 
11 (52.4%) 
10 (47.6%) 
Performance status 
                                        0 
                                        1 
                                        2 
 
544 (50.4%) 
392 (36.3%) 
144 (13.3%) 
 
9 (42.9%) 
4 (19.0%) 
8 (38.1%) 
Stage 
                                        I (bulky) 
                                        II 
                                        III 
                                        IV 
 
79 (7.4%) 
323 (30.1%) 
317 (29.5%) 
355 (33.1%) 
 
1 (4.8%) 
3 (14.3%) 
4 (19.0%) 
13 (61.9%) 
Bulky disease 533 (49.5%) 12 (57.1%) 
B symptoms 489 (45.3%) 12 (57.1%) 
Elevated LDH 701 (64.9%) 18 (85.7%) 
>1 site of extranodal disease 296 (27.4%) 14 (66.7%) 
IPI score 
                                        0 
                                        1 
                                        2 
                                        3 
                                        4 
                                        5 
 
83 (7.7%) 
233 (21.6%) 
306 (28.3%) 
279 (25.8%) 
154 (14.3%) 
25 (2.3%) 
 
1 (4.8%) 
1 (4.8%) 
3 (14.3%) 
6 (28.6%) 
9 (42.9%) 
1 (4.8%) 
MYC-rearrangement (N=359) 36 (10.0%) 0 (0%) 
Double-hit-rearrangement (N=354) 16 (4.5%) 0 (0%) 
 
Table 2: Administration of CNS prophylaxis and incidence of CNS relapse according to sites 
of DLBCL involvement at baseline 
 
Site of lymphoma 
involvement               
N (%) N (%) with  
CNS prophylaxis  
N (%) with  
CNS relapse  
Bone marrow*     101 (9.4%) 42 (41.6%) 6 (5.9%) 
Peripheral blood*    0 (0.0%) NA NA 
Nasal/paranasal sinuses* 6 (0.6%) 6 (100%) 1 (16.7%) 
Orbit* 2 (0.2%) 1 (50.0%) 0 (0%) 
Testis* 14 (1.3%) 10 (71.4%) 0 (0%) 
Bone 63 (5.8%) 29 (46.0%) 3 (4.8%) 
Breast 17 (1.6%) 5 (29.4%) 2 (11.8%) 
Epidural space 0 (0.0%) NA NA 
Kidney and/or adrenal gland 69 (6.4%) 19 (27.5%) 4 (5.8%) 
*Administration of CNS prophylaxis was at the local investigator’s discretion but 
recommended if there was involvement of the following sites at baseline as per protocol 
 
 
Figure 1: Overall survival from study registration 
 
Figure 2: Application of the CNS-IPI risk model 
 
 
p<0.001 
